Join
Live feed
·
NEWSReleasevia Quantisnow
Intercept Pharmaceuticals Inc. logo

Intercept Announces New Phase 2 Data Showing Significant Impact Of OCA-Bezafibrate Combination On Normalization Of Multiple Key Biomarkers Of PBC-Induced Liver Damage At AASLD The Liver Meeting 2023

ByQuantisnow·Wall Street's wire, on your screen.
ICPT· Intercept Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ICPT (Intercept Pharmaceuticals Inc.) and more on Quantisnow.